Approach to the Epidemiology, Disease Management, and Current Challenges in the Management of Generalized Pustular Psoriasis Through a Survey Conducted Among Spanish Dermatologists

• Published in: Actas dermo-sifiliográficas (English ed.) Vol. 115; no. 5; pp. 449 - 457
• Main Authors: Vilarrasa, E, Rivera, R, Eiris, N, Carretero, G, de la Cueva, P, Carrascosa, J M
• Format: Journal Article
• Language: English; Spanish
• Published: Spain 01-05-2024
• Subjects: Cyclosporine - therapeutic use; Delphi Technique; Dermatologists - statistics & numerical data; Dermatology - statistics & numerical data; Disease Management; Female; Health Care Surveys; Humans; Incidence; Male; Practice Patterns, Physicians' - statistics & numerical data; Prevalence; Psoriasis - drug therapy; Psoriasis - epidemiology; Psoriasis - therapy; Retinoids - therapeutic use; Spain - epidemiology; Spain; Epidemiología; Necesidades no cubiertas; Psoriasis pustulosa generalizada; Unmet needs; Generalized pustular psoriasis; Management; Epidemiology; Manejo
• ISSN: 1578-2190
• DOI: 10.1016/j.ad.2023.10.022

Generalized pustular psoriasis (GPP) is a rare and severe inflammatory skin disease characterised by recurrent or intermittent flares. Epidemiological and disease management data in Spain are limited. Our goal was to estimate the epidemiology of GPP, explore its management, and reach consensus on the current challenges faced in Spain.
An electronic survey was submitted to dermatologists from the Spanish Academy of Dermatology and Venereology Psoriasis Working Group. This group is experienced in the management of GPP. It included a Delphi consensus to establish the current challenges.
A total of 33 dermatologists responded to the survey. A 5-year prevalence and incidence of 13.05 and 7.01 cases per million inhabitants, respectively, were estimated. According to respondents, the most common GPP symptoms are pustules, erythema, and desquamation, while 45% of patients present > 1 annual flares. A total of 45% of respondents indicated that flares often require a length of stay between 1 and 2 weeks. In the presence of a flare, 67% of respondents often or always prescribe a non-biological systemic treatment as the first-line therapy [cyclosporine (55%); oral retinoid (30%)], and 45% a biological treatment [anti-TNFα (52%); anti-IL-17 (39%)]. The dermatologists agreed that the main challenges are to define and establish specific therapeutic goals to treat the disease including the patients' perspective on the management of the disease.
Our study describes the current situation on the management of GPP in Spain, increasing the present knowledge on the disease, and highlighting the current challenges faced at the moment.